On September 2, 2026, Norwegian banking giant DNB launched DNB Fund Women's Health, an equity fund that invests exclusively in companies with documented relevance to women's health — a vehicle portfolio manager Anesa Mulabecirovic Sahnoun told Dagens Næringsliv is, as far as DNB knows, the first equity fund in the world with that mandate. Nettavisen reported the launch the same day; the English-language women's health trade press picked it up a week later, with FutureFemHealth flagging it on September 9 as the week's headline signal that women's health has crossed into mainstream institutional investment.

Why It Matters

Women's health has spent a decade being funded by specialist funds, angel syndicates and impact capital — vehicles with strategic patience but limited firepower. A retail-distributed equity fund from a systemically important Nordic bank is a different animal: it puts women's health on the shelf next to tech and energy funds for ordinary Norwegian savers, and it creates persistent public-market demand for the listed end of the category rather than one-off private rounds. The strict eligibility screen is the part sexual wellness founders should read twice. Sahnoun explicitly rejects pinkwashing — marketing to women is not a qualification — which means intimate-care and sexual-wellness brands seeking this kind of institutional exposure will need clinical documentation, not category positioning. That is a durable incentive toward the clinical-evidence turn already visible across pelvic health, menopause and vaginal microbiome products. Two caveats worth holding. The "world's first" claim comes from DNB and is repeated by DN and FutureFemHealth without independent verification, so treat it as the company's characterization. And a 1.21% fee against a 0.2% index alternative sets a high bar: if the fund underperforms, the failure will be read as a verdict on the category rather than on stock selection, which is exactly the asymmetry women's health investing has always suffered from.

Sahnoun is an unusual profile for a fund manager. She is a physician with a doctorate from the University of Bergen and King's College, plus an MBA from the Norwegian School of Economics, and has worked as a portfolio manager at DNB since 2021. To build the book she screened more than a thousand companies manually, landing on roughly 35 to 50 names at launch across pharmaceuticals, diagnostics, medical technology, health services and the consumer market. "My thesis is that women's health is an investment category, and that you can make money from it," she told DN.

Critically for anyone in sexual wellness or femtech pitching this fund, Sahnoun drew a hard line on what qualifies. The fund will not invest in companies that lack documented relevance to women's health — "that a company markets itself to women is not enough," she said. The exposure areas she named stretch well past the fertility-and-contraception box the category is usually shoved into: breast cancer, migraine, osteoporosis, autoimmune disease, endometriosis and menopause. Fees are 1.21% annually including platform fees, against 0.2% for DNB's global index fund — a premium that only pencils out if the thesis is right.

The launch lands in an unusually busy week for women's health capital. FutureFemHealth's September 9 briefing also logged iPremom's €15M seed for first-trimester preeclampsia detection in Spain, India's Nua closing a $50M Series C, Italy's Tensive securing up to €20M in EIB venture debt for breast reconstruction scaffolds, Japan's SiccaNova raising ¥1.25bn for a Sjögren's treatment, and Australia's GonGlobal taking A$1.2m to develop inhaled fertility drugs as an alternative to IVF injections — a backlog of announcements held over from a quiet summer.

Sources

Update — 2026-09-10

Initial entry — story first created.